vs
Side-by-side financial comparison of Insulet Corporation (PODD) and Virtu Financial, Inc. (VIRT). Click either name above to swap in a different company.
Virtu Financial, Inc. is the larger business by last-quarter revenue ($1.1B vs $761.7M, roughly 1.4× Insulet Corporation). Virtu Financial, Inc. runs the higher net margin — 31.6% vs 12.0%, a 19.7% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 30.7%). Over the past eight quarters, Virtu Financial, Inc.'s revenue compounded faster (25.7% CAGR vs 24.9%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
PODD vs VIRT — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $761.7M | $1.1B |
| Net Profit | $91.1M | $346.6M |
| Gross Margin | 69.5% | — |
| Operating Margin | 16.0% | 37.4% |
| Net Margin | 12.0% | 31.6% |
| Revenue YoY | 33.9% | 30.7% |
| Net Profit YoY | 157.3% | 82.8% |
| EPS (diluted) | $1.30 | $1.99 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $761.7M | $1.1B | ||
| Q4 25 | $783.7M | $969.9M | ||
| Q3 25 | $706.3M | $824.8M | ||
| Q2 25 | $649.1M | $999.6M | ||
| Q1 25 | $569.0M | $837.9M | ||
| Q4 24 | $597.5M | $834.3M | ||
| Q3 24 | $543.9M | $706.8M | ||
| Q2 24 | $488.5M | $693.0M |
| Q1 26 | $91.1M | $346.6M | ||
| Q4 25 | $101.6M | $139.9M | ||
| Q3 25 | $87.6M | $77.6M | ||
| Q2 25 | $22.5M | $151.2M | ||
| Q1 25 | $35.4M | $99.7M | ||
| Q4 24 | $100.7M | $94.1M | ||
| Q3 24 | $77.5M | $60.0M | ||
| Q2 24 | $188.6M | $66.6M |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — |
| Q1 26 | 16.0% | 37.4% | ||
| Q4 25 | 18.7% | 35.4% | ||
| Q3 25 | 16.7% | 21.8% | ||
| Q2 25 | 18.7% | 34.7% | ||
| Q1 25 | 15.6% | 26.7% | ||
| Q4 24 | 18.3% | 24.3% | ||
| Q3 24 | 16.2% | 20.8% | ||
| Q2 24 | 11.2% | 22.4% |
| Q1 26 | 12.0% | 31.6% | ||
| Q4 25 | 13.0% | 14.4% | ||
| Q3 25 | 12.4% | 9.4% | ||
| Q2 25 | 3.5% | 15.1% | ||
| Q1 25 | 6.2% | 11.9% | ||
| Q4 24 | 16.9% | 11.3% | ||
| Q3 24 | 14.2% | 8.5% | ||
| Q2 24 | 38.6% | 9.6% |
| Q1 26 | $1.30 | $1.99 | ||
| Q4 25 | $1.42 | $1.54 | ||
| Q3 25 | $1.24 | $0.86 | ||
| Q2 25 | $0.32 | $1.65 | ||
| Q1 25 | $0.50 | $1.08 | ||
| Q4 24 | $1.38 | $1.03 | ||
| Q3 24 | $1.08 | $0.64 | ||
| Q2 24 | $2.59 | $0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $480.4M | $973.2M |
| Total DebtLower is stronger | $18.6M | — |
| Stockholders' EquityBook value | $1.3B | $2.2B |
| Total Assets | $3.0B | $25.1B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $480.4M | $973.2M | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $707.9M | ||
| Q2 25 | — | $752.1M | ||
| Q1 25 | — | $723.6M | ||
| Q4 24 | — | $872.5M | ||
| Q3 24 | — | $701.4M | ||
| Q2 24 | — | $684.8M |
| Q1 26 | $18.6M | — | ||
| Q4 25 | $930.8M | $2.0B | ||
| Q3 25 | $934.9M | $2.0B | ||
| Q2 25 | $939.0M | $1.7B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.4B | $1.7B | ||
| Q2 24 | $1.4B | $1.7B |
| Q1 26 | $1.3B | $2.2B | ||
| Q4 25 | $1.5B | $1.6B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.5B | $1.4B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $998.4M | $1.2B |
| Q1 26 | $3.0B | $25.1B | ||
| Q4 25 | $3.2B | $20.2B | ||
| Q3 25 | $3.0B | $21.3B | ||
| Q2 25 | $3.5B | $19.3B | ||
| Q1 25 | $3.5B | $17.5B | ||
| Q4 24 | $3.1B | $15.4B | ||
| Q3 24 | $3.0B | $14.4B | ||
| Q2 24 | $2.9B | $13.9B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.61× | 1.29× | ||
| Q3 25 | 0.68× | 1.40× | ||
| Q2 25 | 0.64× | 1.24× | ||
| Q1 25 | 1.21× | 1.33× | ||
| Q4 24 | 1.07× | 1.39× | ||
| Q3 24 | 1.21× | 1.41× | ||
| Q2 24 | 1.36× | 1.41× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $113.8M | — |
| Free Cash FlowOCF − Capex | $89.5M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.2% | — |
| Cash ConversionOCF / Net Profit | 1.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $415.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $113.8M | — | ||
| Q4 25 | $183.3M | $518.4M | ||
| Q3 25 | $125.7M | $-68.7M | ||
| Q2 25 | $196.5M | $62.8M | ||
| Q1 25 | $63.8M | $15.0M | ||
| Q4 24 | $147.7M | $599.0M | ||
| Q3 24 | $98.5M | $112.1M | ||
| Q2 24 | $96.5M | $490.8M |
| Q1 26 | $89.5M | — | ||
| Q4 25 | $48.2M | $495.6M | ||
| Q3 25 | $100.1M | $-76.7M | ||
| Q2 25 | $177.9M | $57.6M | ||
| Q1 25 | $51.5M | $9.2M | ||
| Q4 24 | $94.1M | $586.6M | ||
| Q3 24 | $71.8M | $106.2M | ||
| Q2 24 | $74.0M | $486.9M |
| Q1 26 | 11.8% | — | ||
| Q4 25 | 6.2% | 51.1% | ||
| Q3 25 | 14.2% | -9.3% | ||
| Q2 25 | 27.4% | 5.8% | ||
| Q1 25 | 9.1% | 1.1% | ||
| Q4 24 | 15.7% | 70.3% | ||
| Q3 24 | 13.2% | 15.0% | ||
| Q2 24 | 15.1% | 70.3% |
| Q1 26 | 3.2% | — | ||
| Q4 25 | 17.2% | 2.4% | ||
| Q3 25 | 3.6% | 1.0% | ||
| Q2 25 | 2.9% | 0.5% | ||
| Q1 25 | 2.2% | 0.7% | ||
| Q4 24 | 9.0% | 1.5% | ||
| Q3 24 | 4.9% | 0.8% | ||
| Q2 24 | 4.6% | 0.6% |
| Q1 26 | 1.25× | — | ||
| Q4 25 | 1.80× | 3.71× | ||
| Q3 25 | 1.43× | -0.89× | ||
| Q2 25 | 8.73× | 0.42× | ||
| Q1 25 | 1.80× | 0.15× | ||
| Q4 24 | 1.47× | 6.37× | ||
| Q3 24 | 1.27× | 1.87× | ||
| Q2 24 | 0.51× | 7.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
VIRT
| Trading income, net | $789.1M | 72% |
| Commissions, net and technology services | $186.6M | 17% |
| Other | $119.6M | 11% |
